Key facts
- This page summarizes Michael W. Kalb's Form 4 filing for CATALYST PHARMACEUTICALS, INC. (CPRX).
- 7 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 17 Jul 2026, 16:15.
Michael W. Kalb - 15 Jul 2026 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CPRX
- Reported as of
- 15 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jul 2026, 16:15:34 UTC
- Prior SEC filing
- 06 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael W. Kalb
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael W. Kalb filed Form 4 for CATALYST PHARMACEUTICALS, INC. (CPRX) on 17 Jul 2026.
Change
- Previous filing in this sequence was filed on 06 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001678248
Primary reporting owner
Kalb Michael Wayne
- Relationship
- Chief Financial Officer
- Address
- 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES
- Signature
- /s/ Michael W. Kalb
- Signature date
- 17 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CPRX
transaction
Common Stock, par value $0.001 per share
Disposed to Issuer
- Transaction value
- Shares
- -13,665
- Change %
- -100%
- Price
- $31.50*
- Shares after
- 0
- Date
- 15 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CPRX
transaction
Derivative
Options to purchase common stock
Disposed to Issuer
- Transaction value
- Shares
- -257,214
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 257,214
- Exercise price
- $16.81
- Footnotes
- F3, F5
CPRX
transaction
Derivative
Options to purchase common stock
Disposed to Issuer
- Transaction value
- Shares
- -169,248
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 169,248
- Exercise price
- $21.12
- Footnotes
- F3, F5
CPRX
transaction
Derivative
Options to purchase common stock
Disposed to Issuer
- Transaction value
- Shares
- -131,536
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 131,536
- Exercise price
- $22.77
- Footnotes
- F3, F5
CPRX
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- Shares
- -21,416
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,416
- Exercise price
- Footnotes
- F2, F4, F5
CPRX
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- Shares
- -13,788
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,788
- Exercise price
- Footnotes
- F2, F4, F5
CPRX
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- Shares
- -39,701
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 39,701
- Exercise price
- Footnotes
- F2, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Michael W. Kalb is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 5 footnotes
Footnote F1
The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
Footnote F4
In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
Footnote F5
Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.